Barclays Raises AstraZeneca (AZN) Price Target to GBX 7,200

Share on StockTwits

AstraZeneca (LON:AZN) had its price objective lifted by Barclays from GBX 7,000 ($91.47) to GBX 7,200 ($94.08) in a report issued on Friday, Borsen Zeitung reports. The brokerage currently has an “overweight” rating on the biopharmaceutical company’s stock. Barclays‘s price objective suggests a potential upside of 19.74% from the company’s current price.

Several other research analysts have also weighed in on AZN. JPMorgan Chase & Co. set a GBX 7,100 ($92.77) price objective on shares of AstraZeneca and gave the stock a “buy” rating in a research note on Tuesday, January 29th. Shore Capital reissued a “buy” rating on shares of AstraZeneca in a research note on Tuesday, February 5th. Liberum Capital reissued a “hold” rating on shares of AstraZeneca in a research note on Thursday, February 14th. Goldman Sachs Group set a GBX 4,080 ($53.31) price objective on shares of AstraZeneca and gave the stock a “sell” rating in a research note on Thursday, February 14th. Finally, Jefferies Financial Group set a GBX 6,100 ($79.71) price target on shares of AstraZeneca and gave the company a “neutral” rating in a research note on Thursday, February 14th. Three research analysts have rated the stock with a sell rating, six have issued a hold rating and eleven have given a buy rating to the company’s stock. AstraZeneca has an average rating of “Hold” and a consensus price target of GBX 6,425.16 ($83.96).

AstraZeneca stock opened at GBX 6,013 ($78.57) on Friday. AstraZeneca has a fifty-two week low of GBX 5,110 ($66.77) and a fifty-two week high of GBX 6,540 ($85.46). The company has a market cap of $78.88 billion and a P/E ratio of 31.65. The company has a debt-to-equity ratio of 179.66, a quick ratio of 0.57 and a current ratio of 0.75.

In other AstraZeneca news, insider Philip A. J. Broadley acquired 520 shares of the stock in a transaction dated Tuesday, April 30th. The shares were bought at an average cost of GBX 5,738 ($74.98) per share, for a total transaction of £29,837.60 ($38,988.11). Also, insider Marc Dunoyer acquired 8,500 shares of the stock in a transaction dated Tuesday, May 7th. The stock was acquired at an average price of GBX 5,800 ($75.79) per share, for a total transaction of £493,000 ($644,191.82).

About AstraZeneca

AstraZeneca PLC discovers, develops, and commercializes prescription medicines in the areas of oncology, cardiovascular, renal and metabolism, respiratory, autoimmunity, infection, neuroscience, and gastroenterology worldwide. Its marketed products include Arimidex, Casodex/Cosudex, Calquence, Faslodex, Imfinzi, Iressa, Lynparza, Nolvadex, Tagrisso, and Zoladex for oncology diseases; Atacand1/Atacand HCT/Atacand Plus, Brilinta/Brilique, Crestor, Plendil, Seloken/Toprol-XL, Tenormin, and Zestril for cardiovascular diseases; and Bydureon, Byetta, Farxiga/Forxiga, Kombiglyze XR, Komboglyze, Onglyza, Qtern, Symlin, Xigduo, and Xigduo XR for metabolic diseases.

Further Reading: Roth IRA

Analyst Recommendations for AstraZeneca (LON:AZN)

Receive News & Ratings for AstraZeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Analysts Expect Bank of Hawaii Co.  to Announce $1.38 Earnings Per Share
Analysts Expect Bank of Hawaii Co. to Announce $1.38 Earnings Per Share
Soarcoin 1-Day Trading Volume Tops $220.00
Soarcoin 1-Day Trading Volume Tops $220.00
Mason Graphite  Shares Up 5.6%
Mason Graphite Shares Up 5.6%
Continental Gold  Shares Up 0.7%
Continental Gold Shares Up 0.7%
Arcus Biosciences Inc  Short Interest Update
Arcus Biosciences Inc Short Interest Update
Hancock Whitney Corp  Given Average Rating of “Buy” by Analysts
Hancock Whitney Corp Given Average Rating of “Buy” by Analysts


 
© 2006-2019 Zolmax.